心脏衰竭与减少的喷射分数多药丸在印度的实施战略:一个融合并行混合方法研究研究
Anubha Agarwal1, Raji Devarajan2, Salva Balbale3,4
1Division of Cardiology, Department of Medicine and Global Health Center, Washington University in St. Louis, St. Louis, MO, USA.
Global heart
|September 2, 2024
概括
一种用于心力衰竭的多药丸策略,减少排气分数 (HFrEF),在印度医疗保健提供者中显示出适度的可接受性和可行性. 这种方法简化了药物治疗,并可能改善患者的坚持,解决心力衰竭管理的关键挑战.
科学领域:
- 心脏病学 心脏病学
- 实施科学 实施科学
- 公共卫生 公共卫生
背景情况:
- 在全球范围内,特别是印度,心力衰竭与减少喷射分数 (HFrEF) 管理面临着指南导向医学治疗 (GDMT) 坚持的挑战.
- 多药丸策略提供了一个潜在的解决方案,以简化药物治疗方案并改善患者的治疗结果.
研究的目的:
- 探索医生,护士,药剂师和患者对印度HFrEF多药药实施战略的看法.
- 开发一个实施研究逻辑模型,整合定量和定性数据.
主要方法:
- 从2021年1月到2021年4月进行了一项融合平行混合方法研究.
- 从利益相关者调查中获得的定量数据 (n=69) 和从关键信息人采访中获得的定性数据 (n=20) 被整合.
主要成果:
- 该HFrEF多药剂实施策略显示了适度的可接受性 (3.8/5),适当性 (3.6/5),以及可行性 (3.7/5).
- 利益相关者指出了优势,如简化方案和改进的坚持,以及对副作用和住院期间药物中断的担忧.
结论:
- 印度医疗保健提供者认为HFrEF多药剂实施策略是可以接受的,可行的和适当的.
- 开发了一种实施研究逻辑模型,确定特定于背景的决定因素,以指导未来的研究,以改善南亚的心力衰竭护理.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
147
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545


